Hu Juanzhou, Zhang Yinghong, Zhang Wen, Liu Jia, Peng Pan
Medical College, Wuhan University of Science and Technology, 430065 Wuhan, Hubei, China.
Department of Cardiology, Wuhan Asian Heart Hospital affiliated to Wuhan University of Science and Technology, 430022 Wuhan, Hubei, China.
Rev Cardiovasc Med. 2022 Dec 20;23(12):415. doi: 10.31083/j.rcm2312415. eCollection 2022 Dec.
There are almost 2 million adult patients with congenital heart disease in China, and the number of moderate and severe patients is increasing. However, few studies have investigated the risk of serious adverse events (SAE) after catheterization among them. The aim of this study was to identify risk factors for SAE related to cardiac catheterization and to provide the risk scoring model for predicting SAE.
A total of 690 patients with moderate and severe adult patients with congenital heart disease (ACHD) who underwent cardiac catheterization in Wuhan Asian Heart Hospital Affiliated to Wuhan University of Science and Technology from January 2018 to January 2022 were retrospectively collected and subsequently divided into a modeling group and a verification group. A univariate analysis was performed on the identified SAE risk factors, and then significant factors were included in the multivariate logistic regression model to screen for independent predictors of SAE. The receiver operating characteristic curve (ROC) and the Hosmer-Lemeshow test were used to evaluate the discrimination and calibration of the model, respectively.
A SAE occurred in 69 (10.0%) of the 690 catheterization procedures meeting inclusion criteria. The established SAE risk calculation formula was logit() = -6.134 + 0.992 pulmonary artery hypertension (yes) + 1.459 disease severity (severe) + 2.324 procedure type (diagnostic and interventional) + 1.436 cTnI ( 0.028 g/L) + 1.537 NT-proBNP ( 126.65 pg/mL). The total score of the final risk score model based on the effect size of each predictor was 0 to 7, involving pulmonary artery hypertension (1 point), disease severity (1 point), procedure type (2 points), cTnI (1 point) and NT-proBNP (2 points), and the score greater than 3 means high risk. The C-statistic of the area under the ROC curve was 0.840 and 0.911 for the derivation and validation cohorts, respectively. According to the Hosmer-Lemeshow test, the values in the modeling group and the verification group were 0.064 and 0.868, respectively.
The risk prediction model developed in this study has high discrimination and calibration, which can provide reference for clinical prediction and evaluation of SAE risk after cardiac catheterization in patients with moderate and severe ACHD.
中国有近200万成年先天性心脏病患者,中重度患者数量呈上升趋势。然而,很少有研究调查他们在导管插入术后发生严重不良事件(SAE)的风险。本研究旨在确定与心脏导管插入术相关的SAE风险因素,并提供预测SAE的风险评分模型。
回顾性收集2018年1月至2022年1月在武汉科技大学附属武汉亚洲心脏病医院接受心脏导管插入术的690例中重度成年先天性心脏病(ACHD)患者,随后分为建模组和验证组。对已确定的SAE风险因素进行单因素分析,然后将显著因素纳入多因素逻辑回归模型,以筛选SAE的独立预测因素。分别使用受试者工作特征曲线(ROC)和Hosmer-Lemeshow检验评估模型的区分度和校准度。
在符合纳入标准的690例导管插入术中,69例(10.0%)发生了SAE。建立的SAE风险计算公式为logit() = -6.134 + 0.992×肺动脉高压(是)+ 1.459×疾病严重程度(重度)+ 2.324×手术类型(诊断性和介入性)+ 1.436×肌钙蛋白I(≥0.028 μg/L)+ 1.537×N末端脑钠肽前体(≥126.65 pg/mL)。基于每个预测因素的效应大小的最终风险评分模型的总分是0至7分,涉及肺动脉高压(1分)、疾病严重程度(1分)、手术类型(2分)、肌钙蛋白I(1分)和N末端脑钠肽前体(2分);得分大于3分表示高风险。推导队列和验证队列的ROC曲线下面积的C统计量分别为0.840和0.911。根据Hosmer-Lemeshow检验,建模组和验证组的χ²值分别为0.064和0.868。
本研究开发的风险预测模型具有较高的区分度和校准度,可为中重度ACHD患者心脏导管插入术后SAE风险的临床预测和评估提供参考。